Reaffirmed: Five Prime Therapeutics (NASDAQ:FPRX) Buy Rating Kept by Jefferies; $52.0 Target in Place

September 17, 2017 - By Vivian Currie

 Reaffirmed: Five Prime Therapeutics (NASDAQ:FPRX) Buy Rating Kept by Jefferies; $52.0 Target in Place

Investors sentiment decreased to 0.74 in Q4 2016. Its down 0.41, from 1.15 in 2016Q3. It turned negative, as 19 investors sold Five Prime Therapeutics Inc shares while 69 reduced holdings. 16 funds opened positions while 49 raised stakes. 24.63 million shares or 4.67% less from 25.83 million shares in 2016Q3 were reported.

Mufg Americas holds 0% or 376 shares in its portfolio. Alps Advsr Inc holds 0.01% or 36,085 shares in its portfolio. Sterling Cap Mngmt Ltd Llc has 18,678 shares for 0.01% of their portfolio. Alliancebernstein L P invested 0% in Five Prime Therapeutics Inc (NASDAQ:FPRX). State Street reported 0% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). Suntrust Banks has invested 0% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Clinton Grp invested 0.02% in Five Prime Therapeutics Inc (NASDAQ:FPRX). California Pub Employees Retirement System has 23,700 shares for 0% of their portfolio. Oppenheimer And invested in 10,957 shares. Lord Abbett Limited Liability Co accumulated 114,397 shares or 0.02% of the stock. Morgan Stanley has 0% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX). United Cap Fincl Advisers Ltd Limited Liability Company holds 12,601 shares. Bnp Paribas Arbitrage holds 5,128 shares. Franklin Street Advisors Incorporated Nc invested in 0.04% or 5,000 shares. Swiss Bancorp reported 41,900 shares stake.

Five Prime Therapeutics (NASDAQ:FPRX) Rating Reaffirmed

Jefferies now has a $52.0 target price on shares of Five Prime Therapeutics (NASDAQ:FPRX). The target price would suggest a potential upside of 45.21 % from the previous stock close of Five Prime Therapeutics (NASDAQ:FPRX). This rating was revealed to clients and investors in an analyst report on 11 September.

Investors sentiment decreased to 0.74 in Q4 2016. Its down 0.41, from 1.15 in 2016Q3. It turned negative, as 19 investors sold Five Prime Therapeutics Inc shares while 69 reduced holdings. 16 funds opened positions while 49 raised stakes. 24.63 million shares or 4.67% less from 25.83 million shares in 2016Q3 were reported.

Mufg Americas holds 0% or 376 shares in its portfolio. Alps Advsr Inc holds 0.01% or 36,085 shares in its portfolio. Sterling Cap Mngmt Ltd Llc has 18,678 shares for 0.01% of their portfolio. Alliancebernstein L P invested 0% in Five Prime Therapeutics Inc (NASDAQ:FPRX). State Street reported 0% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). Suntrust Banks has invested 0% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Clinton Grp invested 0.02% in Five Prime Therapeutics Inc (NASDAQ:FPRX). California Pub Employees Retirement System has 23,700 shares for 0% of their portfolio. Oppenheimer And invested in 10,957 shares. Lord Abbett Limited Liability Co accumulated 114,397 shares or 0.02% of the stock. Morgan Stanley has 0% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX). United Cap Fincl Advisers Ltd Limited Liability Company holds 12,601 shares. Bnp Paribas Arbitrage holds 5,128 shares. Franklin Street Advisors Incorporated Nc invested in 0.04% or 5,000 shares. Swiss Bancorp reported 41,900 shares stake.

Five Prime Therapeutics Inc (NASDAQ:FPRX) Ratings Coverage

Among 9 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Five Prime Therapeutics has $5500 highest and $33 lowest target. $44.17’s average target is 23.35% above currents $35.81 stock price. Five Prime Therapeutics had 15 analyst reports since July 31, 2015 according to SRatingsIntel. Oppenheimer maintained Five Prime Therapeutics Inc (NASDAQ:FPRX) on Monday, October 19 with “Outperform” rating. The stock has “Buy” rating by Citigroup on Tuesday, October 25. The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) has “Sell” rating given on Tuesday, August 11 by Zacks. As per Friday, December 4, the company rating was maintained by Wells Fargo. On Friday, July 31 the stock rating was initiated by Citigroup with “Buy”. The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) has “Outperform” rating given on Thursday, January 21 by Credit Suisse. Jefferies maintained the stock with “Buy” rating in Wednesday, June 7 report. The firm has “Hold” rating given on Monday, June 5 by BMO Capital Markets. The rating was maintained by Jefferies on Monday, September 11 with “Buy”. The firm has “Market Perform” rating by BMO Capital Markets given on Tuesday, April 12.

The stock increased 1.94% or $0.68 on September 15, reaching $35.81. About 1.21 million shares traded or 296.22% up from the average. Five Prime Therapeutics Inc (NASDAQ:FPRX) has declined 30.56% since September 17, 2016 and is downtrending. It has underperformed by 47.26% the S&P500.

Wall Street await Five Prime Therapeutics Inc (NASDAQ:FPRX) to release earnings on November, 2. Analysts forecast EPS of $-1.32, down exactly $0.60 or 83.33 % from 2014’s $-0.72 EPS. After posting $-1.58 EPS for the previous quarter, Five Prime Therapeutics Inc’s analysts now forecast -16.46 % EPS growth.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology firm focused on discovering and developing protein therapeutics. The company has market cap of $1.03 billion. The Company’s product candidates include Cabiralizumab , which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. It currently has negative earnings.

More notable recent Five Prime Therapeutics Inc (NASDAQ:FPRX) news were published by: Fiercebiotech.com which released: “Five Prime cuts loose from InhibRx immuno-oncology deal” on August 29, 2017, also Globenewswire.com with their article: “Ablexis Announces Licensing of the AlivaMab Mouse to Five Prime Therapeutics” published on September 14, 2017, Seekingalpha.com published: “Five Prime Therapeutics At An Attractive Entry Level” on May 12, 2017. More interesting news about Five Prime Therapeutics Inc (NASDAQ:FPRX) were released by: Seekingalpha.com and their article: “Five Prime Therapeutics: Initiating Coverage With A Buy Rating And A $56 Price …” published on March 31, 2017 as well as Marketwatch.com‘s news article titled: “Five Prime Therapeutics founder, CEO to step down” with publication date: June 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.